Neurocrine Biosciences
NBIX
#1366
Rank
NZ$26.83 B
Marketcap
NZ$269.19
Share price
0.84%
Change (1 day)
25.25%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$7.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$7.46. In 2024 the company made an earnings per share (EPS) of NZ$5.85 an increase over its 2023 EPS that were of NZ$4.40.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$7.4026.43%
2024NZ$5.8533.07%
2023NZ$4.4057.76%
2022NZ$2.7969.47%
2021NZ$1.64-78.21%
2020NZ$7.55990%
2019NZ$0.6981.82%
2018NZ$0.38-113.5%
2017NZ-$2.820.62%
2016NZ-$2.8057.28%
2015NZ-$1.7825.61%
2014NZ-$1.4218.84%
2013NZ-$1.19-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
NZ$0.05193-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.06-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
NZ-$105.59-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$35.52 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.34-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.98-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.96-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.51-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA